Purpose of review Type 1 diabetes (T1D) is now predictable by measuring major islet autoantibodies (IAbs) against insulin and other pancreatic b cells proteins including GAD65 (GADA), islet antigen 2 (IA-2A), and zinc transporter 8 (ZnT8A). The assay technology for IAbs has made great progress; however, several important aspects still need to be addressed and improved.
INTRODUCTION
Type 1 diabetes (T1D) is one of the most common and serious long-term diseases often beginning in childhood. The incidence of T1D is increasing worldwide at 3-5% each year and has doubled in the last two decades [1, 2] . Although T1D is mainly a T-lymphocytes mediated -destruction of insulin producing b cells within pancreatic islets, appearance of islet autoantibodies (IAbs) in peripheral blood is currently the most reliable marker to assess the autoimmune process leading to T1D; it marks the onset of b-cell autoimmunity and determines the disease risk. IAbs usually appear years before overt clinical disease and children with two or more of four major islet autoantibodies to insulin (IAA), GAD65 (GADA), islet antigen 2 (IA-2A), and zinc transport 8 (ZnT8A) have a 70% risk of developing clinical T1D in 10 years and a nearly 100% progression to clinical disease when followed for over two decades [3] . Many national and international screening studies for T1D have being launched in relatives and general population, and these longitudinal studies on preclinical T1D have helped to better understand the natural history of T1D development; define the onset of islet autoimmunity to identify potential triggers; identify individuals for current and upcoming trials to prevent T1D; and finally prevent life-threatening diabetic ketoacidosis.
Through the laboratory proficiency programs and harmonization efforts [4] [5] [6] [7] , a radio-binding assay (RBA) has been well established as the current 'gold' standard assay for all four IAbs. A newly validated nonradioactive IAb assay using electrochemiluminescence (ECL) detection for both IAA and GADA demonstrated higher sensitivity and disease specificity than RBA in several clinical studies, with superior detection of early seroconversion to islet autoimmunity and better discrimination of high-affinity, high-risk autoantibodies from those low-affinity, low-risk signals less or nonrelevant to the disease [8, 9, 10 ]. However, improvements in IAbs assays are still needed to help with large-scale screening in general populations, more efficiently at a lower cost. In this review, we will further discuss two fundamental aspects, sensitivity and disease specificity of autoantibodies for prediction of the risk and the rate of T1D progression. Potential autoantibodies to modified epitopes on protein molecules, posttranslationally modified and chimeric peptides may be a new interesting field to explore. Finally, we will briefly discuss the new generation of autoantibody assay, a multiplexed assay, which will hopefully allow large-scale population screening and point-of-care clinical needs.
TEXT OF REVIEW

Early identification of type 1 diabetes autoimmunity
IAbs are currently the most reliable biomarkers of the autoimmune process leading to T1D and almost all individuals with two or more IAbs will develop clinical T1D over time. The IAbs usually develop sequentially, not simultaneously, and IAA is usually the first IAb to appear in young children followed from birth, which has been further confirmed by recent data from clinical studies [19] . Seroconversion with appearance of the first IAb in the peripheral blood circulation may mark the initiation of islet autoimmunity, an important check point as prospective studies such as The Environmental Determinants of Diabetes in the Young (TEDDY) analyze possible environmental factors contributing to the start of the autoimmune process. Children followed from birth, either from relatives of patients with T1D or general population, usually present with IAA as their first IAb, but older children and young adults often present with GADA first, especially patients with DR3-DQ2 haplotype [20 & ], which has led to the current idea of heterogeneous cause of T1D development, with different primary b-cell autoantigens, varying according to age and genetic background. The current standard RBA for IAbs have been greatly improved through the laboratory proficiency programs and harmonization efforts. However, the IAA assay has proven the most difficult to standardize with relatively wide discrepancies between laboratories in Islet Autoantibody Standardization Program (IASP) workshop, and has not yet achieved a satisfactory level of sensitivity and specificity. A newly developed IAA assay with ECL technology has been validated in multiple clinical studies with higher sensitivity and earlier detection of seroconversion by years than RBA. In the Diabetes Autoimmunity Study in the Young (DAISY), all prediabetic children who were followed to clinical T1D from birth were found almost to have IAA as their first IAb by ECL assay at seroconversion (9); as the data are limited to only one study, it needs to be further validated in other large prospective studies. In addition, IAA has been found to correlate inversely with age in both prevalence and level, with lower frequency and lower levels in older children and adults, which obviously adds more difficulties to effectively identify IAA among individuals beyond childhood. In summary, IAA is an important early marker for initiation of islet autoimmunity and the sensitivity of IAA assay might be a key issue in resolving the current puzzle of T1D cause in terms of primary autoantigen(s). This will be an essential question to be answered in the near future to better understand the underlying mechanisms of initiation of the autoimmune process leading to T1D in both children and adults with different genetic backgrounds. It is also critical to precisely pinpoint the exact time of initial seroconversion as studies such as TEDDY investigate potential environmental triggering factors involved in T1D pathogenesis. In addition, all current IAA assays are not able to distinguish natural IAA from induced insulin antibodies by exogenous insulin usage, and both IAA and insulin antibodies are high-affinity antibodies, although the epitope binding sites might be different. It would be helpful to have an assay that distinguishes IAA from induced insulin antibodies to further aid T1D research as current T1D trials, often require the confirmatory presence of at least one IAb.
Predicting rate of type 1 diabetes progression
Natural history studies of T1D have shown that T1D may begin with seroconversion of single IAb, conversion to multiple IAbs, and finally progression to overt
KEY POINTS
IAA is an important early marker for initiation of islet autoimmunity and the sensitivity of IAA assay might be a key issue in resolving the current puzzle of T1D cause in terms of primary autoantigen(s).
Adding other biomarkers to IAbs such as age, cellular immune markers, metabolic changes, and genetic background, will likely help to predict rate of progression from islet autoimmunity to clinical T1D.
Identification of autoantibodies to neo-antigens or neoepitopes posttranslational modification (PTM) is a new important field which will likely help understand the underlying mechanism of loss of immune tolerance in T1D and provide new potential biomarkers for T1D.
Multiplexed IAb assay combining multiple antibody assays in one well will be a useful tool for general population screening.
clinical diabetes. At initial screening either in first degree relatives of patients with T1D or in general population, IAA or GADA are often detected in isolation whereas IA-2A and ZnT8A are rarely present as a single IAb. Children with single IAb only have a 15% risk of developing T1D [3] after 15 years of follow-up and predictive values with either single IAA or single GADA are low. In several longitudinal studies including DAISY, TrialNet, and TEDDY, our group has shown that prediction of T1D risk in patients with single IAb can be improved by using ECL assay, which is more disease specific [8,10,11 && ]. Figure 1 illustrates better positive prediction values of single IAb by ECL assay compared to RBA for both IAA and GADA (both P < 0.0001) in the TrialNet Pathway to Prevention study. Cumulative risk of T1D development in patients with single IAb by ECL assay is significantly higher than RBA for both GADA (P ¼ 0.0009) and IAA (P < 0.0001; Fig. 2) . Furthermore, recent evidence suggests that patients with either single IAA or single GADA confirmed by ECL assay have metabolic changes of impaired glucose tolerance [14 && ] comparable to patients with multiple IAbs, whereas ECL negative patients showed no signs of impaired glycemia during a median follow-up of 4.7 years. TrialNet Pathway to Prevention patients who were ECL-positive had an overall risk of progression to diabetes within 6 years of 58% compared to 5% for those ECL-negative patients ( Fig. 3a ; P < 0.0001). Survival curves analyzing participants positive for 1 IAb by RBA showed a much higher risk for development of diabetes by year 6 for patients who were ECL positive (23% if both ECL-IAA and ECL-GADA positive, 18% if only ECL-IAA positive, and 21% if only ECL-GADA positive) compared to those patients who were ECL negative (4%; Fig. 3b ; P < 0.0001). When looking at patients positive for at least two IAbs by RBA, the risk for development of diabetes was again much higher for those patients who were ECL positive: 61% by 6 years if both ECL-IAA and ECL-GADA positive, 69% by 4 years if only ECL-IAA positive, and 51% by 6 years if only ECL-GADA positive compared to 22% for those patients who were ECL negative ( Fig. 3c ; P ¼ 0.02).
Progression to diabetes diagnosis after seroconversion varies tremendously from several months to over a decade. Factors involved in rate of progression are poorly understood, although some determinants have been observed to be associated with rate of progression including younger age at seroconversion, number of autoantibodies, higher levels of IAA [21] , and more recently higher levels of IA-2A [ ]. Development of diabetes was also faster in children who became multiple IAbs within 2 years of initial seroconversion than in children who became multiple IAbs above 2 years after seroconversion. Although positivity for multiple IAbs is accurate in predicting risk for T1D, we currently do not have the ability to predict the rate of progression to diabetes in individuals with islet autoimmunity. Adding other biomarkers to IAbs such as age, T and B or other cellular immune markers, metabolic changes, and genetic background, will likely help to predict rate of progression from islet autoimmunity to clinical T1D.
Neo-antigens and neo-epitopes
There is increasing evidence both in animal models and in humans that posttranslational modification (PTM) is a characteristic of antigens in many autoimmune diseases. A recent study [24 && ] published in Science showed that the proteasome-generated spliced peptide pool accounts for one-third of the entire HLA class I immunopeptidome in terms of diversity and one-fourth in terms of abundance, which may have profound implications for the concept of self/nonself peptide presentation, derived from human or pathogen proteomes, with direct implications for autoimmunity. The b-cell is highly susceptible to endoplasmic reticulum and oxidative stress and is potentially a site of alteration in protein alternative splicing and PTMs [25, 26] . There is supporting evidence in T1D that b-cell antigens undergo modifications through these mechanisms, which might be involved in the killing of b cells [27] [28] [29] [30] [31] . Very recently, diabetes-inducing CD4 Tcell clones isolated from NOD mice were found to recognize epitopes formed by covalent cross-linking of proinsulin peptides to chromogranin A and islet amyloid polypeptide present in b-cell secretary granules [32 && ,33
These hybrid proinsulin peptides are antigenic for CD4 T cells from both mice and human, and CD4 T cells from the residual pancreatic islets of organ donors who had T1D were also found to recognize these proinsulin hybrids. The studies of modification of b-cell antigens have been limited to T cells so far with no current studies reported on B cells and autoantibodies. If PTM plays a critical role in initiation and development of the disease, identification of autoantibodies to these neo-antigens or neo-epitopes will be an important approach to gain new evidence of T1D pathogenesis and to help understand the underlying mechanism of loss of immune tolerance in T1D. These autoantibodies will also be new valuable biomarkers for T1D. ], multiplexed assays combining multiple antibody assays in one well are being tested to help with large-scale screening in general populations. There are at least four advantages with multiplex assays (using 4-plex assay as example) compared with current single radioassays: higher throughput capacity: one lab technician is able to complete the assays for three to four times the number of samples that can be handled with current single RBA; lower volume of serum: multiplex assay needs three to four times less serum than current RBA; lower cost: multiplex assay will cost 70% less than total cost for current four single RBAs; nonradioactive: as the multiplex ECL assay does not require radioactivity, we envision increased access to IAbs measurement with this methodology across academic and commercial laboratories.
General population screening
Large-scale screening can be hindered by geographical limitations, with families having to travel significant distances to study centers, as well as aversion to venous blood sampling particularly in young children. A simple, home-based procedure, without the need of a healthcare professional, could improve access to screening and potential prevention studies. Through the TrialNet study group, two pilot studies of feasibility for sampling on both dried blood spots (DBS) [37] and capillary blood samples (CBS) [38 & ] were performed. The IAbs were analyzed and compared with venous blood serum samples. Self-collected DBS or CBS were shown to be a feasible option, preferred by families over venous sampling, with the potential to facilitate screening for T1D risk. In the feasibility study on DBS samples, IAA was not performed because IAA assay on DBS samples was historically challenging with less sensitivity. In a very recent study [39 & ], conditions to elute autoantibodies from DBS on filter paper were optimized and stability of the DBS samples was assessed over time. Eluted DBS IAb measurements were performed for all four IAbs in patients with new-onset T1D and in controls and compared to serum measurements using standard radioassays. Our results demonstrated that IAb measurements, including IAA, from DBS on filter paper strongly correlate to serum levels. Validation studies will be warranted to expand this approach into a general population screening test for T1D risk in the near future.
CONCLUSION
IAbs are currently the best biomarkers for T1D and have greatly contributed to the understanding of the natural history of the T1D autoimmune process and the prediction of risk in both first-degree relatives of patients with T1D and general population. There are still many challenges and room for improvements, Survival analysis was performed for the development of diabetes since initial visit according to ECL positivity using the log-rank test. ECL-GADA/ECL-islet autoantibodies to insulin (IAA) pos, positive for both ECL-GADA and ECL-IAA; ECL-GADA pos, positive for ECL-GADA only; ECL-IAA pos, positive for ECL-IAA only; ECL-GADA/ECL-IAA neg, negative for both ECL-GADA and ECL-IAA [13 especially in understanding the study of T1D in terms of primary autoantigens and to more precisely pinpoint the time of initiation of islet autoimmunity; combining other biomarkers to predict or estimate rate of progression to disease; exploring potential T1D autoantibodies to neo-antigens and neo-epitopes created by PTM mechanism; finally developing an efficient and affordable tool for general population screening and point-of-care.
